Mereo BioPharma Group plc (MREO) Key Metrics
MREO valuation today
Trailing 12 months · as of October 17, 2026- Market cap
- $48.4M
- Enterprise value
- $25.6M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 97.5
- Price / book
- 1.9
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 0.14
MREO key metrics, 2023–2025
Fiscal year ended December 31, 2025 · U.S. dollarsMREO valuation Price multiples at each fiscal year-end price.
MREO returns How much profit the business earns on the capital it uses.
MREO per-share figures Results divided by the shares outstanding at year-end.
MREO financial health Debt, liquidity and how easily interest is covered.
MREO efficiency & capital use Working capital cycle and where the cash goes.
MREO valuation history
MREO returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
MREO debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
MREO price vs earnings per share
MREO key metrics
2023–2025| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Valuation | |||
| Market capitalization | $66.4M | — | $304.7M |
| Enterprise value | $25.6M | — | $253.2M |
| Price / sales | 132.9 | — | 30.5 |
| Price / book | 1.6 | — | 6.0 |
| EV / sales | 51.3 | — | 25.3 |
| Earnings yield | −63.0% | — | −9.7% |
| Free cash flow yield | −46.7% | — | −7.1% |
| Share price at fiscal year-end | $0.42 | $3.50 | $2.31 |
| Per share | |||
| Revenue per share | $0.00 | — | $0.08 |
| Earnings per share | −$0.26 | — | −$0.22 |
| Operating cash flow per share | −$0.19 | — | −$0.16 |
| Free cash flow per share | −$0.19 | — | −$0.16 |
| Cash per share | $0.26 | — | $0.44 |
| Book value per share | $0.26 | — | $0.38 |
| Tangible book value per share | $0.25 | — | $0.37 |
| Capex per share | $0.00 | — | $0.00 |
| Debt per share | $0.00 | — | $0.05 |
| Shares outstanding | 159.4M | — | 131.9M |
| Returns & profitability | |||
| Return on equity (ROE) | −82.2% | −77.6% | −58.3% |
| Return on assets (ROA) | −68.5% | −60.5% | −44.3% |
| Return on tangible assets | −92.2% | −57.1% | −45.0% |
| Free cash flow margin | — | — | −215.5% |
| Financial health | |||
| Total debt | $202,000 | $6.4M | $6.0M |
| Cash & short-term investments | $41.0M | $69.8M | $57.4M |
| Net debt | −$40.8M | −$63.4M | −$51.5M |
| Debt / equity | 0.00 | 0.11 | 0.12 |
| Debt / assets | 0.00 | 0.08 | 0.09 |
| Net debt / EBITDA | — | −58.25 | — |
| Current ratio | 10.46 | 5.40 | 6.72 |
| Quick ratio | 10.46 | 5.40 | 6.59 |
| Interest coverage | -150.0 | -34.6 | -9.9 |
| Working capital | $40.7M | $60.9M | $54.3M |
| Invested capital | $126,000 | −$2.4M | −$932,000 |
| Tangible asset value | $40.4M | $60.3M | $49.4M |
| Net current asset value | $40.0M | $59.3M | $47.8M |
| Graham net-net per share | $0.24 | — | $0.34 |
| Capital allocation | |||
| Capex / revenue | 4.0% | — | 4.2% |
| Capex / depreciation | 0.02 | 0.64 | 0.39 |
| Stock-based compensation / revenue | 1,519.6% | — | 49.2% |
| R&D / revenue | 3,553.2% | — | 174.2% |
| SG&A / revenue | 4,601.6% | — | 184.2% |
| Efficiency | |||
| Days sales outstanding | 1,910.0 | — | 136.2 |
| Days of inventory on hand | — | — | 176.8 |
| Days payables outstanding | 5,177.2 | 802.5 | 332.7 |
| Cash conversion cycle (days) | -3,267.2 | — | -19.6 |
| Receivables turnover | 0.19 | 0.00 | 2.68 |
| Payables turnover | 0.07 | 0.45 | 1.10 |
| Inventory turnover | — | — | 2.06 |
| Asset turnover | 0.01 | 0.00 | 0.15 |
| Average receivables | $2.6M | $3.5M | $3.7M |
| Average payables | $1.9M | $2.4M | $2.3M |
| Average inventory | — | — | $1.2M |
| Intangibles / total assets | 1.1% | 0.8% | 1.6% |
Computed from MREO's annual financial statements (latest annual report filed March 19, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
MREO valuation and financial ratios
Mereo BioPharma earned a return on equity of −82.2% in fiscal 2025. It ended the year with $0.2 million of debt and $41.0 million in cash and short-term investments, a net cash position of $40.8 million.
See the MREO income statement, the MREO chart for price history, or the MREO stock overview for the latest quote and news.
MREO key metrics FAQ
What is Mereo BioPharma's return on equity?
Mereo BioPharma's return on equity (ROE) was −82.2% in fiscal 2025: net income of -$41.9 million on average shareholders' equity of $50.9 million.
How much debt does Mereo BioPharma have?
Mereo BioPharma had total debt of $0.2 million at the end of fiscal 2025, a debt-to-equity ratio of 0.00 and more cash than debt.
What is Mereo BioPharma's free cash flow yield?
Mereo BioPharma generated -$31.0 million of free cash flow in fiscal 2025, a free cash flow yield of −46.7% on its market value at year-end ($66.4 million).
What is Mereo BioPharma's current ratio?
Mereo BioPharma's current ratio was 10.46 at the end of fiscal 2025: current assets were 10.46 times current liabilities.